The finalization of a $20 million Series A funding round this April, with an investor option to expand the total to $50 million based on Phase III clinical milestones and Japanese pharmaceutical licensing, represents a paradigm shift in the treatment of respiratory disease.
At the heart of this momentum is Trisyntec, which is redefining the intersection of diagnostic intelligence and patient care. By integrating predictive AI with a data-driven, Non-Invasive Medical Imaging (NMMI) diagnostic platform, Trisyntec is transforming a high-performance wearable device into a comprehensive ecosystem for treating TB, COPD, and Sleep Apnea.
The Intelligence Behind the Therapy
Trisyntec serves as the digital backbone of Trisyntec’s respiratory mission, providing the sophisticated "brain" that powers their wearable therapeutic device. This innovation centers on a digitally focused pulmonary disease diagnostic interface that utilizes NMMI technology to monitor patient health with unprecedented precision. By incorporating embedded sensors, the system captures real-time patient experience data and transmits it directly to an AI-driven epidemiology platform. This integration enables a critical shift from reactive treatment to proactive management, using predictive analytics to identify trends in pulmonary health and intervene before patients reach a crisis point.
Real-World Impact: Beyond the Lab
The power of this collaboration is best illustrated by the patients it serves. Recently, an 86-year-old woman suffering from Stage 3 COPD and heart arrhythmia, a condition where traditional pharmaceutical beta-blockers had failed, Trisyntec integrated a wearable belt into her daily routine for 30 minutes, twice a day. The results were transformative; her respiratory issues began to normalize almost instantly, and in just two weeks, her walking capacity increased from a restricted 100 meters to over 500 meters. By the fourth week, her heart began working smoothly without pharmaceutical intervention through the activation of the parasympathetic nervous system, fostering a state of natural healing and relaxation. These outcomes are backed by data showing a 40% enhancement in breathing function, improved oxygenation within just 30 minutes (a feat no drug can currently claim), and a remarkable 43% increase in deep sleep phases.
The Global Roadmap: India and Beyond
Trisyntec’s technology is now moving into a critical validation phase. Through Trisyntec’s strategic partner, Clinexel Life Sciences, they have secured a tandem relationship with the Indian government’s Biotechnology Industry Research Assistance Council (BIRAC). This partnership will launch an accelerated, adaptive Phase III clinical trial involving 200 participants over 90 days. These trials serve as the final "check-off" for major global stakeholders, including a Tokyo-based pharmaceutical giant that recently dispatched executives to Amsterdam to witness the device's effectiveness firsthand.
Looking Ahead: A Five-Product Pipeline
As Trisyntec moves toward the end of 2026, they anticipate entering into two major pharmaceutical licensing agreements, one specifically targeting COPD and the other for Obstructive Sleep Apnea. With their AI platform at the helm, their pulmonary pipeline is set to evolve into a five-product suite. Trisyntec is not just building a device; they are building a world-class infrastructure to mitigate the global prevalence of pulmonary disease, one data point and one breath at a time.
